Wall Street analysts expect Cencora (COR) to post quarterly earnings of $4.05 per share in its upcoming report, which indicates a year-over-year increase of 8.6%. Revenues are expected to be $85.97 billion, up 5.5% from the year-ago quarter.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Ahead of a company's earnings disclo ...

Core Viewpoint - Cencora (COR) is expected to report strong first-quarter fiscal 2026 results, with positive revenue and earnings growth driven by pharmaceutical utilization trends and specialty-focused assets [1][3][7] Group 1: Financial Estimates - The Zacks Consensus Estimate for revenues is $85.97 billion, reflecting a 5.5% increase from the prior-year quarter [2] - The consensus estimate for earnings is $4.05 per share, indicating an 8.6% improvement from the previous year's figure [2] Group 2: Performance Drivers - Cencora's performance is anticipated to be supported by strong drug volumes and the U.S. Healthcare Solutions segment, which is expected to be the primary earnings driver [3][5][7] - The integration of Retina Consultants of America (RCA) is likely to contribute positively to sales and margins [3][4] Group 3: Segment Analysis - The U.S. Healthcare Solutions segment is projected to generate sales of $76.72 billion, benefiting from specialty distribution and MSO platforms [6][7] - The International Healthcare Solutions segment is expected to maintain growth, with sales estimated at $7.45 billion, supported by stable trends in Europe and World Courier momentum [6][8] Group 4: Margin and Growth Outlook - Margin performance is expected to remain favorable due to mix benefits from specialty distribution and MSO-related services, despite higher interest expenses from acquisition financing [4][5] - Specialty utilization, particularly in Part B drugs, is anticipated to support above-trend operating income growth [5]

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: Barclays upgraded Zillow Group (ZG) to Equal Weight from Underweight with a price target of $72, up from $66. The firm believes a lot of downside risks are priced into shares. Rosenblatt upgraded Fortinet (FTNT) to Buy from Neutral with a price target of $100, up from $85, ahead of the Q4 report on February 5. ...

Core Viewpoint - Cencora, Inc. has appointed Ellen Cooper as a new independent director, effective January 20, 2026, bringing significant leadership experience from Lincoln Financial and Goldman Sachs [1] Group 1: Leadership Appointment - Ellen Cooper is the Chairman, President, and CEO of Lincoln Financial, indicating her strong leadership background [1] - Prior to her role as CEO, she held positions as Executive Vice President, Chief Investment Officer, and Head of Enterprise Risk and Annuity Solutions at Lincoln Financial, showcasing her extensive experience in investment and risk management [1] - Ms. Cooper's previous experience at Goldman Sachs adds to her qualifications, enhancing the board's expertise [1]

Core Viewpoint - Pharmaceutical distributors, traditionally viewed as low-margin utilities, are evolving, with Cencora (COR) indicating a shift in operational strategy to potentially enhance profitability and service offerings [1] Industry Summary - The pharmaceutical distribution sector has been characterized by low margins, primarily serving the volume-driven needs of the healthcare industry [1] - Cencora has historically operated within this low-margin framework but is now exploring new operational strategies [1]

Core Insights - Cencora is a global pharmaceutical services healthcare company that ships over 1 billion medications annually through its MSO investments [2] - The company reported a 9% year-over-year revenue increase and a 16% increase in both adjusted operating income and adjusted diluted EPS, while generating $3 billion in free cash flow [2] Strategic Focus - Cencora emphasizes its purpose-driven approach, aiming to create healthier futures, which is a key indicator of its operational outcomes [3] - The company is strategically focused on four drivers, including digital transformation, optimizing business processes, and leveraging advanced analytics and AI to enhance business operations [3]

Cencora (NYSE:COR) FY Conference Summary Company Overview - Cencora is a global pharmaceutical services healthcare company that ships over a billion medications annually and employs 51,000 team members [2][3] - The company reported a 9% year-over-year revenue increase and a 16% increase in both adjusted operating income and adjusted diluted EPS, generating $3 billion in free cash flow [2] Core Strategic Drivers - **Digital Transformation**: Focus on optimizing business processes through advanced analytics and AI [3] - **Talent Development**: Commitment to career growth for employees [3] - **Productivity Improvement**: Continuous focus on enhancing operational efficiency [4] - **Growth-Oriented Investments**: Prioritization of investments that align with future strategies [4] Recent Developments - Cencora completed the acquisition of Retina Consultants of America and plans to accelerate the acquisition of OneOncology, which is expected to enhance the company's MSO platform [5][8] - The company announced a $1 billion investment in supply chain infrastructure through 2030, focusing on expanding capacity and cold chain logistics [6] Financial Guidance - Long-term operating income growth guidance was raised from 5%-8% to 6%-9%, and EPS guidance was increased from 8%-12% to 9%-13% [14][15] - Following the OneOncology acquisition announcement, long-term guidance was further raised to 7%-10% for operating income and 10%-14% for EPS [15] Market Position and Growth - Cencora is well-positioned in the specialty pharmaceuticals market, which is experiencing significant innovation and growth [7] - The MSO platform is expected to drive additional growth, enhancing relationships with providers and pharmaceutical manufacturers [7][23] Challenges and Opportunities - The company is monitoring potential impacts from changes in pharmaceutical pricing policies, particularly regarding WAC decreases and their effect on physician reimbursement [25][26] - Cencora has a strong strategic global sourcing department that has successfully managed gross margin dollars despite pricing pressures [27] International Segment - The international segment, which accounts for about 20% of operating income, is expected to see 5%-8% growth, with improvements anticipated in global specialty logistics and a more focused portfolio [59][60] Share Repurchase and Capital Deployment - Share repurchases have been paused due to the OneOncology acquisition, with plans to resume after prioritizing debt repayment [66] Conclusion - Cencora is focused on enhancing its pharmaceutical-centric strategy, investing in growth-oriented opportunities, and maintaining strong financial performance while navigating market challenges [10][66]

J.P. Morgan Healthcare Conference Bob Mauch, President and Chief Executive Officer JANUARY 12, 2026 Cautionary note regarding forward-looking statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Words such as "aim," "anticipate," "believe," "can," "continue," "could," "estimate," "expec ...

Core Insights - Medical supplies stocks are typically not seen as high-return investments due to thin margins and regulatory pressures, making outperformance unlikely in a challenging macro environment [1] - However, companies like Cardinal Health, McKesson, and Cencora have achieved significant stock returns over the past year, outperforming the broader market with gains of 66.4%, 39.5%, and 42.2% respectively [2] Company Performance Cardinal Health - Cardinal Health has shown a turnaround with double-digit operating earnings growth across all segments in Q1 of fiscal 2026, indicating broad improvement [4][8] - Revenues increased by 22% year over year to $64 billion, driven by strong pharmaceutical demand and GLP-1 volumes, with the Pharmaceutical and Specialty Solutions segment profit rising by 26% [5] - The company is expanding its specialty business, including the acquisition of Solaris Health, aimed at enhancing provider relationships [6][8] - Cardinal Health generated $1.3 billion in adjusted free cash flow and returned $500 million to shareholders through dividends and buybacks [9] McKesson - McKesson reported 10% revenue growth to $103 billion and 39% adjusted EPS growth in Q2 of fiscal 2026, showcasing its operational excellence [11] - The Oncology and Multispecialty segment saw revenues jump by 32% and operating profit surge by 71%, driven by strong specialty volumes and acquisitions [12] - The company generated $2.2 billion in free cash flow and returned $907 million to shareholders, primarily through share repurchases [13] Cencora - Cencora's performance reflects the strength of specialty-focused distribution, with 6% revenue growth and 15% adjusted EPS growth in Q4 of fiscal 2025 [16] - Operating income rose by 20% year over year, supported by strong specialty demand and the acquisition of Retina Consultants of America [17] - The company plans to invest approximately $1 billion through 2030 to enhance distribution capacity and cold-chain infrastructure [18]

Core Insights - Cencora, Inc. (COR) is positioned for growth due to a strong U.S. Healthcare Solutions business and new product launches, although competition remains a concern [1][8] - The company's shares have increased by 13.4% over the past six months, outperforming the industry gain of 12.1% and the S&P 500 Index increase of 13.6% [1] Company Overview - Cencora is one of the largest pharmaceutical service companies globally, focusing on drug distribution and related services to lower healthcare costs and enhance patient outcomes, with a market capitalization of $67.15 billion [2] Financial Performance - The bottom line for Cencora is expected to improve by 11.9% over the next five years, with earnings surpassing estimates in the last four quarters, averaging a surprise of 5.51% [3] Positive Growth Drivers - Cencora benefits from sustained pharmaceutical utilization trends, particularly in specialty drugs for oncology and retina, supported by favorable demographics and ongoing pharmaceutical innovations [4] - As a leading distributor aligned with top manufacturers, Cencora is well-positioned for long-term organic operating income growth of 6-9% [5] - The expansion into management services organizations (MSOs) enhances growth and strategic positioning, allowing for higher-value services and reinforcing Cencora's pharmaceutical-centric strategy [6] Market Dynamics - The rising adoption of biosimilars in the Part B market is a significant profitability driver, generating higher margins than branded products, which supports operating income expansion [10] - Strong physician adoption in oncology and retina reinforces the benefits of biosimilars, positioning Cencora to capitalize on ongoing innovation and product transitions [11] Challenges - The international segment is experiencing declines due to reduced clinical trial activity and a slower recovery in biotech services, with operating income down 2% in the fourth quarter of fiscal 2025 [12] - Although GLP-1 sales remain strong, growth has moderated to 19%, and the loss of a low-margin grocery-channel customer is impacting revenue growth, leading to a revised U.S. revenue outlook [13] Estimate Trends - There has been a positive estimate revision trend for fiscal 2026, with the Zacks Consensus Estimate for earnings increasing from $17.59 to $17.62 per share, and first-quarter fiscal 2026 revenues expected to improve by 5.4% year-over-year [14]